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Background:  Diabetes (DM) and chronic kidney disease (CKD) are common co-morbidities in patients with heart failure (HF). However, 
there is uncertainty on optimal DM management with these co-morbidities, and usage patterns of anti-hyperglycemic medications (AHM) 
among these complex patients are poorly understood.
methods:  Using Get With the Guidelines-HF linked to Medicare claims, we assessed AHM use in HF patients with DM discharged 
between 1-1-2006 and 9-30-2011 and summarized AHM use by renal function. Renal contraindicated AHM use for patients with 
GFR<30mL/min/1.73m2 was assessed per prescribing information (Table, asterisk for AHMs with renal contraindication).
results:  Among 8,791 patients with HF and DM, 1,512 (17.2%) had GFR <30. Median age was 77 (interquartile range 71-83) and 34% 
had ejection fraction <40%. Metformin and sulfonylurea use was lower and insulin use higher among patients with GFR <30 vs. GFR 
≥30. Among patients with GFR <30, 535 (35.3%) filled prescriptions for renal contraindicated AHMs. There was a trend for less renal 
contraindicated AHM use over time (Cochran-Mantel-Haenszel row-mean score test p=0.048).
conclusion:  Patients with HF, DM, and CKD are commonly treated with anti-hyperglycemic medications that have renal contraindications. 
Further studies are needed to evaluate outcomes based on these use patterns.
Table: Use of Anti-Hyperglcemic Medications After Hospitalization for Heart Failure
GFR<30mL/min/1.73m2
(n=1,512)
30≤ GFR <60mL/
min/1.73m2
(n=4,313)
GFR≥60mL/min/1.73m2
(n=2,861) p-value^
Therapy
Metformin* 3.5 13.5 29.5 <0.001
Sulfonylurea* 26.9 34.3 32.9 <0.001
Meglitinide* 4.9 3.6 3.0 0.005
Dipeptidyl peptidase-4-
inhibitor* 4.9 5.3 4.7 0.477
Glucagon-like peptide-1 
agonist* 0.2 0.4 0.5 0.284
Alpha-glucosidase 
inhibitor* 0.6 0.6 0.4 0.426
Amylin Analog 0.1 0.1 0.1 1.00
Thiazolidinedione 5.7 7.2 6.4 0.117
Insulin 47.4 40.9 33.0 <0.001
Number of Diabetes 
Medications Filled within 
90 days
<0.001
0 25.0 24.3 26.4
1 58.8 51.6 44.3
2 13.5 18.9 22.9
>2 2.7 5.2 6.5
*anti-hyperglycemic medications with labeling to adjust dose or avoid use in patients with renal impairment
^Pearson chi-square p-value
